A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)

计划入组 74 人 · 首次发布于 2019 年 7 月 16 日

Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

计划入组 223 人 · 首次发布于 2023 年 5 月 25 日

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

计划入组 145 人 · 首次发布于 2015 年 9 月 17 日

Caplacizumab(Cablivi)

GPVI inhibitors (thrombotic disorders)

program targeting acquired resistance mechanism

US THROMBOTIC MICROANGIOPATHY ALLIANCE

United States

Galderma Group AG

Switzerland

Lexeo Therapeutics

United States

EU Approves Sanofi's Cablivi as First Targeted Therapy for Rare Blood Clotting Disorder aTTP

Sanofi Secures Chinese Approval for Two Rare Blood Disorder Therapies Qfitlia and Cablivi

Global Thrombocytopenia Clinical Trials Market Sees Significant Growth in 2025